The 5-hydroxytryptamine2a Receptor is Involved in (+)-norfenfluramine-induced Arterial Contraction and Blood Pressure Increase in Deoxycorticosterone Acetate-salt Hypertension.
From: Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824-1317, USA. niwei@msu.edu
The Journal of pharmacology and experimental therapeutics
- Publish Date: May 2007
- ISSN: 0022-3565
- Volume: 321
- Issue: 2
- Pages: 485-91
- Medium: Print
- Language: English
- Citation (JAMA): Ni Wei, Fink Gregory D, Watts Stephanie W, et al. The 5-hydroxytryptamine2a Receptor is Involved in (+)-norfenfluramine-induced Arterial Contraction and Blood Pressure Increase in Deoxycorticosterone Acetate-salt Hypertension.. J. Pharmacol. Exp. Ther. May 2007;321:485-91
Abstract
The highly effective anorexigen (+)-fenfluramine was widely used to control body weight until the association with primary pulmonary hypertension and valvular heart disease. (+)-Norfenfluramine is the major hepatic metabolite of (+)-fenfluramine and is primarily responsible for the anorexic effect as well as side effects. We reported that (+)-norfenfluramine causes vasoconstriction and a blood pressure increase in rats with normal blood pressure via the 5-hydroxytryptamine (5-HT)2A receptor. With the knowledge that (+)-norfenfluramine also has affinity for 5-HT2B receptors and that arterial 5-HT2B receptor expression is up-regulated in deoxycorticosterone acetate (DOCA)-salt hypertension, we tested the hypothesis that (+)-norfenfluramine-induced vasoconstriction and pressor effects are potentiated in DOCA-salt hypertensive rats in a 5-HT2 receptor-dependent manner. Contractions of arteries were measured using an isolated tissue bath system or myograph. Mean arterial blood pressure was measured in chronically instrumented conscious rats. Effects of (+)-norfenfluramine in stimulating arterial contraction (leftward shift versus SHAM, aorta, 5.13-fold; renal artery, 1.95-fold; mesenteric resistance artery, 1.77-fold) and raising blood pressure were significantly enhanced in hypertension. In arteries from both normotensive and hypertensive rats, (+)-norfenfluramine-induced contraction in aorta was inhibited by 5-HT2A receptor antagonists, ketanserin and LY53857 (4-isopropyl-7-methyl-9-(2-hydroxy-1-meth ylpropoxycarbonyl)4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline), but not by the 5-HT2B receptor antagonist, LY272015 [6-chloro-5-methyl-N-(5-quinolinyl)-2,3-dihydro-1H-indole-1-carboxamide]. Ketanserin (3 mg/kg) reduced (+)-norfenfluramine-induced pressor response in both SHAM and DOCA rats. Our results demonstrate that (+)-norfenfluramine-induced arterial contraction and blood pressure increases are potentiated in DOCA-salt hypertensive rats. However, it is the 5-HT2A receptor and not the 5-HT2B receptor that participates in these effects.
Mesh Headings (Keywords): Animals, Blood Pressure, Desoxycorticosterone, Hypertension, Male, Norfenfluramine, Organic Chemicals, Rats, Rats, Sprague-Dawley, Receptor, Serotonin, 5-HT2A, Sodium Chloride, Vasoconstriction
Check for Full Text / PubMed Unique Identifier (PMID): 17289838
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.